Clinical Characteristics and Management of Patients with Mucopolysaccharidosis II (MPS II) in the United States from the Hunter Outcome Survey
Back to course
Pdf Summary
Asset Subtitle
Presenting Author - Barbara K. Burton, MD; Co-Author - Can Ficicioglu, MD PhD; Co-Author - Helio Pedro, MD; Co-Author - Ravi Pathak, PhD, MBA; Co-Author - Ian Robinson, MPH; Co-Author - Ekaterina Wright, MD; Co-Author - Joseph Muenzer, MD PhD;
Meta Tag
Enzyme Replacement Therapy
Lysosomal Diseases
Metabolic Disorder
Therapy
Co-Author Can Ficicioglu, MD PhD
Co-Author Helio Pedro, MD
Co-Author Ravi Pathak, PhD, MBA
Co-Author Ian Robinson, MPH
Co-Author Ekaterina Wright, MD
Co-Author Joseph Muenzer, MD PhD
Presenting Author Barbara K. Burton, MD
Keywords
Mucopolysaccharidosis II
Hunter syndrome
lysosomal storage disease
iduronate-2-sulfatase
enzyme replacement therapy
recombinant idursulfase
Hunter Outcome Survey
cognitive impairment
organ system abnormalities
respiratory failure

© 2025 American College of Medical Genetics and Genomics. All rights reserved.

Powered By